Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01836029 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01836029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
October 14, 2013
Completion date
September 19, 2016
Enrollment
195 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck